company background image
TLX

Telix Pharmaceuticals ASX:TLX Stock Report

Last Price

AU$6.92

Market Cap

AU$2.2b

7D

-3.1%

1Y

10.9%

Updated

27 Jan, 2023

Data

Company Financials +

Telix Pharmaceuticals Limited

ASX:TLX Stock Report

Mkt Cap: AU$2.2b

TLX Stock Overview

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.

TLX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Telix Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Telix Pharmaceuticals
Historical stock prices
Current Share PriceAU$6.92
52 Week HighAU$8.20
52 Week LowAU$3.55
Beta2.45
1 Month Change2.52%
3 Month Change1.02%
1 Year Change10.90%
3 Year Change367.57%
5 Year Change1,093.10%
Change since IPO798.70%

Recent News & Updates

Recent updates

Shareholder Returns

TLXAU BiotechsAU Market
7D-3.1%-1.4%0.6%
1Y10.9%11.8%3.5%

Return vs Industry: TLX underperformed the Australian Biotechs industry which returned 15.9% over the past year.

Return vs Market: TLX exceeded the Australian Market which returned 5.4% over the past year.

Price Volatility

Is TLX's price volatile compared to industry and market?
TLX volatility
TLX Average Weekly Movement6.5%
Biotechs Industry Average Movement9.1%
Market Average Movement8.6%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.5%

Stable Share Price: TLX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: TLX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aChris Behrenbruchhttps://telixpharma.com

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases.

Telix Pharmaceuticals Limited Fundamentals Summary

How do Telix Pharmaceuticals's earnings and revenue compare to its market cap?
TLX fundamental statistics
Market CapAU$2.19b
Earnings (TTM)-AU$118.89m
Revenue (TTM)AU$28.73m

76.2x

P/S Ratio

-18.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TLX income statement (TTM)
RevenueAU$28.73m
Cost of RevenueAU$12.24m
Gross ProfitAU$16.49m
Other ExpensesAU$135.38m
Earnings-AU$118.89m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.38
Gross Margin57.40%
Net Profit Margin-413.76%
Debt/Equity Ratio0%

How did TLX perform over the long term?

See historical performance and comparison